icometrix Competitors

Elucid is a Boston-based medical technology company using histology-validated software to provide physicians with a cost-effective means to optimize treatment decisions for patients with cardiovascular disease. Advanced clinical insight from Elucid's CTA analysis equips physicians with critical information designed to enable precision medicine. Elucid is the first non-invasive software to quantify atherosclerotic plaque characteristics compared to histopathology, including Lipid Rich Necrotic Core. The company has published studies for its derivation of fractional flow reserve (FFRct) based on the vasodilative capacity of the vessel wall. Elucid's unique information informs improved treatment decisions by physicians leading to better patient outcomes, improved quality of care, and reduced healthcare costs.

ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ: NDRA) is a developer of enhanced ultrasound technologies. ENDRA is developing a next generation Thermo-Acoustic Enhanced UltraSound (TAEUS™) platform to enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only with CT & MRI - at a fraction of the cost, and at the point-of-care. ENDRA's first TAEUS application will focus on the quantification of fat in the liver, for early detection and monitoring of Non-Alcoholic Fatty Liver Disease (NAFLD). ENDRA's goal is to bring new capabilities to ultrasound - thereby broadening access to better healthcare. For more information, please visit www.endrainc.com. Non-Alcoholic Fatty Liver Disease (NAFLD) is a condition closely associated with obesity, diabetes, hepatitis-C and certain genetic predispositions in which fat accumulates in the liver. NAFLD affects over 1 billion people globally and is estimated to cost the U.S healthcare system over $100B annually. NAFLD is often asymptomatic and, If left untreated, NAFLD can progress to inflammation (NASH), tissue scarring (fibrosis), cell death (cirrhosis) and liver cancer. By 2025, NAFLD is forecast to be the greatest root cause of liver transplants. The only tools currently available for diagnosing and monitoring NAFLD are impractical: expensive Magnetic Resonance Imaging (MRI) or an invasive surgical biopsy.

Resoundant, Inc. is a medical technology company founded by Mayo Foundation for Medical Education and Research and is located in Rochester, MN. Resoundant is dedicated to improving patient care and diagnosis accuracy by making Magnetic Resonance Elastography (MRE) available around the world. MRE is cleared by the FDA as an MR add-on technology. Currently, Resoundant MRE is installed in over 800 locations world-wide and is sold as an upgrade to MRI scanner manufactured by Philips, GE Healthcare and Siemens. MRE technology uses low frequency mechanical vibrations that harmlessly travel through a patient's body. These waves are generated by a specially developed acoustic driver system that is synchronized with a standard MRI scanner. The propagating waves travel faster through stiff tissue than through soft tissue, and a sophisticated computer algorithm works with the MRI image data to generate very accurate, quantitative measures of tissue stiffness that are displayed graphically. The result is a quantitative 3-D map of tissue stiffness in the targeted area of the patient’s body. Currently, MRE is being used clinically for the diagnosis liver fibrosis, but research into additional diagnostic capabilities for other areas of the body such as brain, muscle, breast, kidney, spine and the heart show great promise for many more clinical applications.